Kirjahaku

NATIONAL BESTSELLER - The gripping story of Elizabeth Holmes and Theranos--one of the biggest corporate frauds in history--a tale of ambition and hubris set amid the bold promises of Silicon Valley, rigorously reported by the prize-winning journalist. With a new Afterword covering her trial and sentencing, bringing the story to a close. "Chilling ... Reads like a thriller ... Carreyrou tells the Theranos story] virtually to perfection." --The New York Times Book ReviewIn 2014, Theranos founder and CEO Elizabeth Holmes was widely seen as the next Steve Jobs: a brilliant Stanford dropout whose startup "unicorn" promised to revolutionize the medical industry with its breakthrough device, which performed the whole range of laboratory tests from a single drop of blood. Backed by investors such as Larry Ellison and Tim Draper, Theranos sold shares in a fundraising round that valued the company at more than $9 billion, putting Holmes's worth at an estimated $4.5 billion. There was just one problem: The technology didn't work. Erroneous results put patients in danger, leading to misdiagnoses and unnecessary treatments. All the while, Holmes and her partner, Sunny Balwani, worked to silence anyone who voiced misgivings--from journalists to their own employees.

In 2014, Theranos founder and CEO Elizabeth Holmes was widely seen as the next Steve Jobs: a brilliant Stanford dropout whose startup "unicorn" promised to revolutionize the medical industry with its breakthrough device, which performed the whole range of laboratory tests from a single drop of blood. Backed by investors such as Larry Ellison and Tim Draper, Theranos sold shares in a fundraising round that valued the company at more than $9 billion, putting Holmes's worth at an estimated $4.5 billion. There was just one problem: The technology didn't work. Erroneous results put patients in danger, leading to misdiagnoses and unnecessary treatments. All the while, Holmes and her partner, Sunny Balwani, worked to silence anyone who voiced misgivings-from journalists to their own employees.Rigorously reported and fearlessly written, Bad Blood is a gripping story of the biggest corporate fraud since Enron-a tale of ambition and hubris set amid the bold promises of Silicon Valley.

'I couldn’t put down this thriller . . . a book so compelling that I couldn't turn away' – Bill Gates'A story so incredible you'd think it was fiction' – James PattersonWinner of the Financial Times/McKinsey Business Book of the Year Award.The shocking true story of the breathtaking rise and collapse of Theranos, the multibillion-dollar biotech startup founded by Elizabeth Holmes, written by the prize-winning journalist who first broke the story and pursued it to the end.Seen as the female Steve Jobs, Theranos founder and CEO Elizabeth Holmes was a brilliant Stanford dropout whose startup ‘unicorn’ promised to revolutionize the medical industry with a machine that would make blood testing significantly faster and easier. Backed by wealthy investors, Theranos sold shares that valued the company at more than $9 billion.There was just one problem: the technology didn’t work . . .Despite threats of legal action, brave whistleblowers started to talk. They revealed a culture of intimidation and secrecy, technology that repeatedly failed, results sent to real patients that were incorrect but upon which life-changing medical decisions were being made, with devastating consequences.The riveting story behind The Dropout, in Bad Blood, John Carreyrou investigates the biggest corporate fraud since Enron, a tale of ambition and scandal set amid the bold promises of Silicon Valley.'A tale of corporate fraud and legal browbeating that reads like a crime thriller' – TIME, The 10 Best Nonfiction Books of the Year

The shocking true story of the biggest corporate fraud since Enron, a gripping cautionary tale set amid the bold promises and gold-rush frenzy of Silicon Valley.

Elizabeth Holmes (f. 1984) har altid været bange for nåle. Hendes livsmission var at opfinde en nem og billig metode til at tage blodprøver, der kunne afdække en lang række sygdomme. Som 19-årig droppede hun ud af universitetet og stiftede biotekvirksomheden Theranos, der ti år senere blev vurderet til en værdi på ti milliarder dollars. I 2015 var hun USA’s både yngste og rigeste selvskabte kvindelige milliardær. En lang række af USA’s mest magtfulde folk lovpriste den ambitiøse iværksætter, der kom på forsiden af magasiner som Forbes og Fortune og blev udråbt som den kvindelige Steve Jobs. Der var kun ét problem. Hendes produkt virkede ikke. Det stoppede hende dog ikke. Hun afviste al kritik, fyrede alle medarbejdere, der sagde hende imod, og fortsatte med at markedsføre sit produkt over for investorer. Hun fik endda sit apparat ind i USA’s næststørste apotekerkæde, hvor amerikanerne fik taget blodprøver. Elizabeth Holmes og Theranos blev afsløret af bogens forfatter, John Carreyrou, der har interviewet over 150 personer til bogen, heriblandt 60 tidligere ansatte hos Theranos.Kåret til årets businessbog 2018 af Financial Times og McKinsey. Udnævnt til en af årtiets ti bedste nonfiktionbøger af The Times.

Silicon Valley älskade Theranos, företaget som skulle revolutionera hälsovården. Med sitt banbrytande blodtestsystem lovade grundaren och vd:n Elizabeth Holmes att en droppe blod skulle räcka för att mäta hundratals värden och identifiera en lång rad sjukdomar. Riskkapitalisterna och dignitärerna flockades runt den karismatiska ledaren som länge ansågs vara en kvinnlig Steve Jobs.Theranos nådde ett marknadsvärde på 9 miljarder dollar och Holmes egen berömmelse växte ohejdat. Hennes ansikte prydde snart omslagen på flera tidningar och magasin och Time Magazine utsåg henne till en av världens mest inflytelserika personer. Det fanns bara ett problem: teknologin bakom Holmes visionära affärsidé fungerade aldrig.Ont blod är den osannolika men sanna berättelsen om Theranos uppgång och fall, författad av den prisbelönade journalisten John Carreyrou, som var först med att avslöja bluffen i The Wall Street Journal.

Et ajakirjandus on jätkuvalt neljas võim, seda kinnitab see raamat ilma igasuguse kahtluseta. Wall Street Journali uuriv ajakirjanik John Carreyrou on suutnud midagi erakordset: kirjutada tõsielul põhineva romaani, mille mõju reaalsele elule me alles hakkame nägema, kui raamatu peategelane, Ränioru ajaloo suurimas pettuses süüdistatud noor ärinaine Elizabeth Holmes sel sügisel Californias kohtu ette astub. Kriminaaljuurdlus tema tegevuse üle algaski suuresti just tänu Carreyrou ajakirjanduslikule juurdlusele!Ehkki lõplik sõna on kohtul, USA-s siis 12-liikmelisel Holmesi kaaskodanikest koosneval vandemeeste kogul, dokumenteerib Carreyrou detailhaaval vereanalüüside-revolutsiooni lubanud firma Theranose loo. Esialgu eduloo, mis muutis selle idufirma loonud Elizabeth Holmesi mõneks ajaks paberil miljardäriks, aga kui selgus, et kõik põhines Suurel Valel, varises Theranos kokku nagu kaardimaja.Kuigi Theranose tõus ja langus on teada, lugesin raamatut ikkagi kui peadpööritaval kiirusel arenevat põnevusromaani, mis kinnitab, et päriselu võib pakkuda veelgi hingematvamaid sõite Ameerika mägedel, kui parimgi põnevuskirjandus."Vere pettus" peaks olema kõigile maailma muutmise ideedega noortele ettevõtjatele lausa kohustuslik kirjandus. Ja ka ajakirjanikele, kellele Carreyrou kinnitab, et meie tööl on siiski suur kaal.- Neeme Raud, ajakirjanikSee lugu on veel hullumeelsem, kui ma arvasin. Kui olin lugemist alustanud, oli mul võimatu raamatut käest panna. Siin on kõik olemas: keerukad pettused, ärimaailma intriigid, ajakirjade kaanelood, rikutud peresuhted - ja kunagi ligi 10 miljardile dollarile hinnatud ettevõtte allakäik.- Bill Gates